- Home
- SLG vs RNA Comparison
SLG vs RNA Comparison
Compare SLG & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLG
- RNA
- Stock Information
- Founded
- SLG 1980
- RNA 2012
- Country
- SLG United States
- RNA United States
- Employees
- SLG N/A
- RNA N/A
- Industry
- SLG Real Estate Investment Trusts
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- SLG Real Estate
- RNA Health Care
- Exchange
- SLG Nasdaq
- RNA Nasdaq
- Market Cap
- SLG 4.6B
- RNA 4.0B
- IPO Year
- SLG 1997
- RNA 2020
- Fundamental
- Price
- SLG $57.62
- RNA $36.88
- Analyst Decision
- SLG Hold
- RNA Strong Buy
- Analyst Count
- SLG 16
- RNA 14
- Target Price
- SLG $65.81
- RNA $67.71
- AVG Volume (30 Days)
- SLG 1.1M
- RNA 2.6M
- Earning Date
- SLG 07-16-2025
- RNA 08-08-2025
- Dividend Yield
- SLG 5.42%
- RNA N/A
- EPS Growth
- SLG N/A
- RNA N/A
- EPS
- SLG N/A
- RNA N/A
- Revenue
- SLG $640,547,000.00
- RNA $8,927,000.00
- Revenue This Year
- SLG N/A
- RNA N/A
- Revenue Next Year
- SLG $1.50
- RNA $196.18
- P/E Ratio
- SLG N/A
- RNA N/A
- Revenue Growth
- SLG N/A
- RNA N/A
- 52 Week Low
- SLG $45.15
- RNA $21.51
- 52 Week High
- SLG $82.81
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- SLG 38.70
- RNA 65.42
- Support Level
- SLG $58.50
- RNA $34.25
- Resistance Level
- SLG $60.72
- RNA $37.59
- Average True Range (ATR)
- SLG 1.61
- RNA 2.08
- MACD
- SLG -0.47
- RNA 0.40
- Stochastic Oscillator
- SLG 10.32
- RNA 74.58
About SLG SL Green Realty Corp
SL Green Realty is one of the largest Manhattan property owners and landlords, with interest in around 32 million square feet of wholly owned and joint-venture office space. The company has additional property exposure through its limited portfolio of well-located retail space. It operates as a real estate investment trust.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.